azd5423
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2009 (NCT00963183)
Timeline
Indications
Mechanism of action
- Glucocorticoid receptorINHIBITOR
NR3C1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd5423
- azd5423
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01635985 | Phase 1 | Aug 1, 2012 | AstraZeneca |
| NCT01555099 | Phase 2 | Apr 1, 2012 | AstraZeneca |
| NCT01338350 | Phase 1 | Jun 1, 2011 | AstraZeneca |
| NCT01310322 | Phase 1 | Apr 1, 2011 | AstraZeneca, IQVIA |
| NCT01225549 | Phase 2 | Nov 1, 2010 | AstraZeneca |
| NCT01037504 | Phase 1 | Jan 1, 2010 | AstraZeneca, IQVIA |
| NCT00963183 | Phase 1 | Aug 1, 2009 | AstraZeneca, IQVIA |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 7 | 7 | 2 | 2009 |
| IQVIA | For profit | 3 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1